# Spectral AI, Inc.: financial statements, quarterly

MDAI · Nasdaq · CIK 1833498 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mdai.md) · [Financials](/companies/mdai/financials.md) · [Filings](/companies/mdai/filings.md) · [Insiders](/companies/mdai/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mdai/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3.4](/filings/0001213900-24-095006.md) | [5.3 d](/filings/0001213900-25-026157.md) | [6.3](/filings/0001213900-25-044076.md) | [7.5](/filings/0001213900-25-075125.md) | [8.2](/filings/0001213900-25-109409.md) | [7.6 d](/filings/0001213900-26-033808.md) | [6.7](/filings/0001213900-26-055226.md) | [5.1](/filings/0001213900-26-087764.md) | [3.8](/filings/0001213900-25-109409.md) | [4.1 d](/filings/0001213900-26-033808.md) | [4.0](/filings/0001213900-26-055226.md) | [3.5](/filings/0001213900-26-087764.md) |
| Cost of revenue | $m | [2.0](/filings/0001213900-24-095006.md) | [2.9 d](/filings/0001213900-25-026157.md) | [3.4](/filings/0001213900-25-044076.md) | [4.2](/filings/0001213900-25-075125.md) | [4.5](/filings/0001213900-25-109409.md) | [4.3 d](/filings/0001213900-26-033808.md) | [3.5](/filings/0001213900-26-055226.md) | [2.8](/filings/0001213900-26-087764.md) | [2.2](/filings/0001213900-25-109409.md) | [2.2 d](/filings/0001213900-26-033808.md) | [2.0](/filings/0001213900-26-055226.md) | [2.4](/filings/0001213900-26-087764.md) |
| Gross profit | $m | [1.5](/filings/0001213900-24-095006.md) | [2.4 d](/filings/0001213900-25-026157.md) | [2.9](/filings/0001213900-25-044076.md) | [3.3](/filings/0001213900-25-075125.md) | [3.7](/filings/0001213900-25-109409.md) | [3.3 d](/filings/0001213900-26-033808.md) | [3.2](/filings/0001213900-26-055226.md) | [2.3](/filings/0001213900-26-087764.md) | [1.6](/filings/0001213900-25-109409.md) | [1.8 d](/filings/0001213900-26-033808.md) | [2.0](/filings/0001213900-26-055226.md) | [1.1](/filings/0001213900-26-087764.md) |
| Research and development | $m | not reported | not reported | [4.3](/filings/0001213900-25-044076.md) | not reported | not reported | not reported | [3.6](/filings/0001213900-26-055226.md) | [1.5](/filings/0001213900-26-087764.md) | [6.2 d](/filings/0001213900-25-109409.md) | not reported | [2.0](/filings/0001213900-26-055226.md) | [1.7](/filings/0001213900-26-087764.md) |
| Operating income | $m | [(4.2)](/filings/0001213900-24-095006.md) | [(2.9) d](/filings/0001213900-25-026157.md) | [(2.1)](/filings/0001213900-25-044076.md) | [(2.4)](/filings/0001213900-25-075125.md) | [(0.9)](/filings/0001213900-25-109409.md) | [(1.1) d](/filings/0001213900-26-033808.md) | [(0.9)](/filings/0001213900-26-055226.md) | [(2.1)](/filings/0001213900-26-087764.md) | [(3.3)](/filings/0001213900-25-109409.md) | [(2.2) d](/filings/0001213900-26-033808.md) | [(2.0)](/filings/0001213900-26-055226.md) | [(4.3)](/filings/0001213900-26-087764.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | [0.0](/filings/0001213900-25-109409.md) | not reported | [0.0](/filings/0001213900-26-055226.md) | [0.1](/filings/0001213900-26-087764.md) | [0.3](/filings/0001213900-25-109409.md) | [0.3 d](/filings/0001213900-26-033808.md) | [0.3](/filings/0001213900-26-055226.md) | [0.4](/filings/0001213900-26-087764.md) |
| Income tax | $m | [(0.1)](/filings/0001213900-24-095006.md) | [(0.0) d](/filings/0001213900-25-026157.md) | [0.0](/filings/0001213900-25-044076.md) | [0.1](/filings/0001213900-25-075125.md) | [0.0](/filings/0001213900-25-109409.md) | [(0.0) d](/filings/0001213900-26-033808.md) | [0.1](/filings/0001213900-26-055226.md) | [(0.0)](/filings/0001213900-26-087764.md) | [0.0](/filings/0001213900-25-109409.md) | [(0.0) d](/filings/0001213900-26-033808.md) | [(0.0)](/filings/0001213900-26-055226.md) | [0.2](/filings/0001213900-26-087764.md) |
| Net income | $m | [(10.6)](/filings/0001213900-24-095006.md) | [(3.5) d](/filings/0001213900-25-026157.md) | [(3.2)](/filings/0001213900-25-109409.md) | [(2.9)](/filings/0001213900-25-109409.md) | [(1.5)](/filings/0001213900-25-109409.md) | [(7.6) d](/filings/0001213900-26-033808.md) | [2.9](/filings/0001213900-26-087764.md) | [(8.0)](/filings/0001213900-26-087764.md) | [(3.6)](/filings/0001213900-25-109409.md) | [1.1 d](/filings/0001213900-26-033808.md) | [(3.4)](/filings/0001213900-26-087764.md) | [(4.2)](/filings/0001213900-26-087764.md) |
| Diluted EPS | $ per share | [(0.77)](/filings/0001213900-24-095006.md) | not reported | [(0.19)](/filings/0001213900-25-044076.md) | [(0.16)](/filings/0001213900-25-075125.md) | [(0.08)](/filings/0001213900-25-109409.md) | not reported | [0.11](/filings/0001213900-26-055226.md) | [(0.31)](/filings/0001213900-26-087764.md) | [(0.13)](/filings/0001213900-25-109409.md) | not reported | [(0.11)](/filings/0001213900-26-055226.md) | [(0.13)](/filings/0001213900-26-087764.md) |
| Basic EPS | $ per share | [(0.77)](/filings/0001213900-24-095006.md) | not reported | [(0.19)](/filings/0001213900-25-044076.md) | [(0.16)](/filings/0001213900-25-075125.md) | [(0.08)](/filings/0001213900-25-109409.md) | not reported | [0.13](/filings/0001213900-26-055226.md) | [(0.31)](/filings/0001213900-26-087764.md) | [(0.13)](/filings/0001213900-25-109409.md) | not reported | [(0.11)](/filings/0001213900-26-055226.md) | [(0.13)](/filings/0001213900-26-087764.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating, us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | period not labelled (2024-03-20) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [4.8](/filings/0001213900-24-095006.md) | [4.6](/filings/0001213900-26-033808.md) | [10.2](/filings/0001213900-24-040950.md) | [6.9](/filings/0001213900-24-067651.md) | [3.7](/filings/0001213900-24-095006.md) | [5.2](/filings/0001213900-25-109409.md) | [14.1](/filings/0001213900-25-044076.md) | [10.5](/filings/0001213900-25-075125.md) | [10.5](/filings/0001213900-25-109409.md) | [15.4](/filings/0001213900-26-087764.md) | [11.7](/filings/0001213900-26-055226.md) | [14.0](/filings/0001213900-26-087764.md) |
| Current assets | $m | [9.9](/filings/0001213900-25-026157.md) | not reported | [14.9](/filings/0001213900-24-040950.md) | [11.7](/filings/0001213900-24-067651.md) | [9.5](/filings/0001213900-24-095006.md) | [10.1](/filings/0001213900-26-033808.md) | [18.7](/filings/0001213900-25-044076.md) | [14.0](/filings/0001213900-25-075125.md) | [13.5](/filings/0001213900-25-109409.md) | [19.5](/filings/0001213900-26-087764.md) | [16.0](/filings/0001213900-26-055226.md) | [17.8](/filings/0001213900-26-087764.md) |
| Total assets | $m | [10.7](/filings/0001213900-25-026157.md) | not reported | [15.5](/filings/0001213900-24-040950.md) | [13.9](/filings/0001213900-24-067651.md) | [11.6](/filings/0001213900-24-095006.md) | [12.1](/filings/0001213900-26-033808.md) | [20.7](/filings/0001213900-25-044076.md) | [16.0](/filings/0001213900-25-075125.md) | [15.3](/filings/0001213900-25-109409.md) | [21.4](/filings/0001213900-26-087764.md) | [17.7](/filings/0001213900-26-055226.md) | [19.4](/filings/0001213900-26-087764.md) |
| Current liabilities | $m | [12.4](/filings/0001213900-25-026157.md) | not reported | [17.5](/filings/0001213900-24-040950.md) | [16.1](/filings/0001213900-24-067651.md) | [13.1](/filings/0001213900-24-095006.md) | [17.6](/filings/0001213900-26-033808.md) | [13.3](/filings/0001213900-25-044076.md) | [16.2](/filings/0001213900-25-075125.md) | [15.8](/filings/0001213900-25-109409.md) | [20.6](/filings/0001213900-26-087764.md) | [21.3](/filings/0001213900-26-055226.md) | [19.9](/filings/0001213900-26-087764.md) |
| Total liabilities | $m | [12.4](/filings/0001213900-25-026157.md) | not reported | [17.5](/filings/0001213900-24-040950.md) | [18.2](/filings/0001213900-24-067651.md) | [15.9](/filings/0001213900-24-095006.md) | [19.3](/filings/0001213900-26-033808.md) | [22.3](/filings/0001213900-25-044076.md) | [25.2](/filings/0001213900-25-075125.md) | [23.5](/filings/0001213900-25-109409.md) | [27.1](/filings/0001213900-26-087764.md) | [26.5](/filings/0001213900-26-055226.md) | [31.5](/filings/0001213900-26-087764.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | [1.0](/filings/0001213900-24-095006.md) | [2.8](/filings/0001213900-25-044076.md) | [7.5](/filings/0001213900-25-044076.md) | [7.6](/filings/0001213900-25-075125.md) | [6.6](/filings/0001213900-25-109409.md) | [5.5](/filings/0001213900-26-087764.md) | [4.5](/filings/0001213900-26-055226.md) | [11.1](/filings/0001213900-26-087764.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.8](/filings/0001213900-26-087764.md) |
| Shareholders' equity | $m | [(2.1)](/filings/0001213900-26-033808.md) | not reported | [(2.5)](/filings/0001213900-25-109409.md) | [(4.7)](/filings/0001213900-25-109409.md) | [(4.8)](/filings/0001213900-25-109409.md) | [(7.3)](/filings/0001213900-26-087764.md) | [(1.6)](/filings/0001213900-26-087764.md) | [(9.2)](/filings/0001213900-26-087764.md) | [(8.2)](/filings/0001213900-25-109409.md) | [(5.7)](/filings/0001213900-26-087764.md) | [(8.8)](/filings/0001213900-26-087764.md) | [(12.1)](/filings/0001213900-26-087764.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt, us-gaap:LongTermDebtNoncurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(5,338) d](/filings/0001213900-24-095006.md) | [(2,375) d](/filings/0001213900-25-026157.md) | [(2,680)](/filings/0001213900-25-044076.md) | [(5,362) d](/filings/0001213900-25-075125.md) | [(1,626) d](/filings/0001213900-25-109409.md) | [469 d](/filings/0001213900-26-033808.md) | [(1,505)](/filings/0001213900-26-055226.md) | [(3,362) d](/filings/0001213900-26-087764.md) | [(2,501) d](/filings/0001213900-25-109409.md) | [(2,552) d](/filings/0001213900-26-033808.md) | [(3,728)](/filings/0001213900-26-055226.md) | [(4,097) d](/filings/0001213900-26-087764.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [13.1](/filings/0001213900-23-086995.md) | [13.2](/filings/0001213900-24-040950.md) | [13.2](/filings/0001213900-24-067651.md) | [13.8](/filings/0001213900-24-095006.md) | [16.6](/filings/0001213900-25-044076.md) | [17.6](/filings/0001213900-25-075125.md) | [17.9](/filings/0001213900-25-109409.md) | [24.0](/filings/0001213900-26-055226.md) | [25.4](/filings/0001213900-26-087764.md) | [26.3](/filings/0001213900-25-109409.md) | [31.8](/filings/0001213900-26-055226.md) | [32.1](/filings/0001213900-26-087764.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 32,184,928 at 2026-08-11, from the cover of the [10-Q filed 2026-08-11](/filings/0001213900-26-087764.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.